Is retatrutide approved by the MHRA in the UK?

No. Retatrutide has no marketing authorisation from the Medicines and Healthcare products Regulatory Agency for human use in the UK. It remains an investigational compound still moving through Phase 3 clinical trials, which places it in a different regulatory category to licensed medicines such as semaglutide or tirzepatide.

How much weight loss did retatrutide show in clinical trials?

In the Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., n=338), participants receiving the highest dose over 48 weeks recorded average weight loss of up to 24.2%, with the trial still ongoing at its cutoff point, meaning the final figure may have been higher. These are trial results, not a guarantee of individual outcomes, and do not describe any dosing protocol.

Why do retatrutide prices vary so much between sellers?

Because it carries no MHRA marketing authorisation, retatrutide is not sold through a regulated pharmacy price structure. Listed prices vary with claimed purity, batch size, laboratory testing costs, and the absence of any standard reference price, which makes price alone an unreliable signal of quality.

Retatrutide in the UK: MHRA Status and What the Trial Data Shows

The short answer: retatrutide holds no MHRA marketing authorisation for human use in the UK and is still moving through Phase 3 trials. That single fact explains almost everything else people ask about it, from why listed prices swing so widely to why a glossy Certificate of Analysis is not the same thing as regulatory approval.

The Direct Answer

Retatrutide is a triple hormone receptor agonist, acting on GLP-1, GIP, and glucagon receptors, developed by Eli Lilly and still under clinical investigation. It is not an authorised medicine anywhere in the UK, the EU, or the US. The Medicines and Healthcare products Regulatory Agency (MHRA) has not granted it a marketing authorisation for human use, which means no UK pharmacy, clinic, or prescriber can legally supply it as a licensed medicine. Everything circulating outside that framework is, by definition, unlicensed, regardless of how it is labelled or marketed.

A compound still inside Phase 3 trials has not finished being evaluated. Treating trial-stage data as a finished verdict is the single most common mistake in how retatrutide gets discussed online.

Is Retatrutide Legal to Buy in the UK?

Legality here depends on supply, not simple possession. Supplying an unlicensed medicinal product for human use in the UK is an offence under the Human Medicines Regulations 2012, enforced by the MHRA. Retatrutide has not completed the regulatory review that licensed GLP-1 medicines have passed, so it sits entirely outside that approved supply chain. The safest working position is to treat it as an unlicensed research compound with no MHRA-assessed safety or quality status, and to speak to a licensed healthcare professional before making any decision involving it.

What Does the Clinical Trial Data Actually Show?

The most-cited data point comes from a Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.), which enrolled 338 adults with obesity. Participants on the highest weekly dose recorded average weight loss of up to 24.2% at 48 weeks, with the trial's weight-loss curve still trending downward at the cutoff, suggesting the final result may have gone further had the trial run longer. This is a meaningfully larger reported effect size than most Phase 2 data for earlier GLP-1 compounds, which is part of why retatrutide draws so much attention. The full methodology and dataset are indexed on PubMed. Lilly's Phase 3 programme, publicly referred to as TRIUMPH, was still recruiting and reporting through 2025 and 2026, and no UK or EU regulatory filing had concluded as of this review.

How Does Retatrutide's UK Status Compare to Semaglutide and Tirzepatide?

People searching for retatrutide often assume it sits in the same regulatory category as the GLP-1 medicines already available on UK prescription. It does not. The comparison below sets out the actual difference in status, which is the piece most generic summaries skip.

UK Regulatory Status — Compared

Semaglutide (Wegovy, Ozempic) — holds MHRA marketing authorisation; available by prescription through licensed UK pharmacies and clinics.

Tirzepatide (Mounjaro) — holds MHRA marketing authorisation; available by prescription through licensed UK pharmacies and clinics.

Retatrutide — no MHRA marketing authorisation; still in Phase 3 clinical trials; not legally available through any licensed UK supply route.

Reviews from the European Medicines Agency follow a comparable sequence for EU-wide authorisation, and as of this review no EMA opinion on retatrutide had been published either. Until that changes on either side, retatrutide's status is simply not comparable to a licensed medicine, no matter how similar the mechanism sounds.

Why Do Retatrutide Prices Vary So Much?

Because there is no licensed product, there is no regulated reference price either. A licensed medicine's cost is anchored by MHRA-approved manufacturing standards, pharmacy margins, and (for NHS use) NICE appraisal. None of that framework applies here. Listed prices for retatrutide vials instead reflect claimed purity, batch size, whatever independent testing a seller chooses to commission, and simple market positioning, with no regulator checking that the number on the label matches the vial. A low price is not evidence of a bargain, and a high price is not evidence of quality; price alone tells a buyer almost nothing reliable about what is actually in the vial.

What Should Appear on a Retatrutide Certificate of Analysis?

A credible COA names the specific batch in question, not the compound generically, and reports results from an independent, accredited third-party laboratory rather than in-house testing by the seller. For a peptide of this type, that typically means HPLC purity testing at 98% or above and LC-MS identity confirmation, with the laboratory's name and accreditation detail stated rather than implied. Our separate guide to reading a UK peptide COA walks through each field in detail. None of this changes retatrutide's regulatory status; an excellent COA describes a batch, not a licence.

What Are the Known Side Effects Reported in Trials?

Published trial data describes gastrointestinal effects, including nausea, diarrhoea, constipation, and vomiting, as the most frequently reported, broadly consistent with the pattern seen across other GLP-1-class compounds. Discontinuation due to adverse events occurred in a minority of the highest-dose group in the 2023 Phase 2 trial. These figures come from a supervised clinical trial setting with defined monitoring, and do not describe outcomes for unlicensed, unsupervised use of unverified material obtained outside that setting, which carries its own separate and largely undocumented risk profile.

Summary

Retatrutide has no MHRA marketing authorisation in the UK and remains a Phase 3 investigational compound, a materially different regulatory position from licensed medicines like semaglutide and tirzepatide. Its Phase 2 data, published in the New England Journal of Medicine in 2023, reported weight loss of up to 24.2% in a 338-person trial, among the larger effect sizes reported for this drug class to date. Listed prices vary because no regulated reference price exists outside a licensed supply chain, and a strong-looking COA confirms a batch, not a licence. Before acting on any claim about retatrutide, consult a licensed healthcare professional and treat its regulatory status as unresolved.

Retatrutide in the UK: What the MHRA Status and Trial Data Actually Show